Search

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Cardiometabolic Diseases

We are looking for new early-science collaborations and invite you to join our expanding community of innovation partners in CardioMetabolic diseases.

Big Little Things: In cancer, small things make a big impact

Little things can be a big deal when you are living with or treating cancer. “Big Little Things” celebrates the small things that have a big impact.

Boehringer Ingelheim and Zealand Pharma Advance to Phase 2 Clinical Testing in NASH and Obesity

Low-WAC interchangeable biosimilar is now available

Adalimumab-adbm, our interchangeable biosimilar to Humira, now available at a low wholesale acquisition cost.

Cyltezo®, first and only FDA-approved Interchangeable biosimilar to Humira®, now commercially available in the U.S.

Europe’s Largest Initiative Launches to Accelerate Therapy Development for COVID-19 and Future Coronavirus Threats

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

FDA approves additional formulation of biosimilar

US FDA approves additional formulation of Cyltezo® (adalimumab-adbm). See Important Safety Information including Boxed Warning, Prescribing Information, Medication Guide and Instructions for Use.

FDA Approves Pradaxa® (dabigatran etexilate mesylate) for Treatment and Reduction in the Risk of Recurrence of Deep Venous Thrombosis and Pulmonary Embolism

Canine Lyme Disease: What You Need to Know | Boehringer Ingelheim US

Click here to discover all you need to know about lyme disease in dogs; causes, symptoms, prevention, detection and treatment.

J-Code Issued for SPEVIGO

Boehringer Ingelheim receives permanent J-code for SPEVIGO, indicated for the treatment of generalized pustular psoriasis flares in adults

Evolving the Unwearable Collection

Boehringer Ingelheim will partner with the Fashion Institute of Technology in New York to introduce a fifth design as part of The Unwearable Collection™

Update on sNDA for fibrosing ILD in children and adolescents

Press release providing an update on FDA review of sNDA in children and adolescents with fibrosing interstitial lung disease (ILD)

FDA accepts sNDA for children/adolescents with fibrosing ILD

U.S. FDA accepts sNDA for OFEV® (nintedanib) for the potential treatment of children and adolescents aged 6-17 with fibrosing interstitial lung disease

Exploring T-cells in cancer

Lamine Mbow, our Global Head of Cancer Immunology and Immune Modulation, shares our approach to immuno-oncology, highlighting our investigational T-cell engagers platform and how we are driving innovation to potentially deliver meaningful advances to peop

Data Show Safety of Pradaxa® (dabigatran etexilate) in Children | Boehringer Ingelheim US

BI announces results from 2 pediatric studies of PRADAXA, presented at the ISTH Congress in Melbourne. View ISI, PI and Med Guide.

Flying animals to safety with Greater Good Charities

Watch as Julie Ryan-Johnson volunteers to take care of animals being brought to new homes following the Maui wildfires.

Spesolimab prevented generalized pustular psoriasis flares in Effisayil™ 2 trial

Boehringer Ingelheim announces InPedILD PhaseIII trial results

Boehringer Ingelheim Subsidiaries and Affiliate Companies

Thinking differently could eradicate some areas of retinal disease

Retinal disease could be eradicated by thinking differently. Degenerative eye conditions can be cured with a patient-first approach, says Dr Victor Chong.

US FDA approves the Cyltezo® Pen, a new autoinjector option, ahead of July 1 commercial launch

Boehringer Ingelheim Cares Product Donations Program

Expanded Access Programs

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers